Treace Medical Concepts Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$206.3Mnext fiscal year
FY EPS (est.)
-$0.91next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly47.2MTarget: Reaffirmed full-year 2026 revenue guidance of $202 million to $212 million
Gross Margin Quarterly79.3%Target: Maintain strong margins near historical ~80% level
Cash and Marketable Securities Quarterly51.9MTarget: Targeting a ~50% reduction in cash usage versus 2025
Watch Items
- Product Mix Shift and ASP PressuresTrigger: Further decline in average selling price (ASP) or shift to lower-priced products impacting gross margins below 78%Action: Re-evaluate commercial strategy, pricing models, and sales force incentives to prioritize higher-margin procedure bundles.
- Commercialization of SuperBite and SpeedXM PlatformsTrigger: Delay in full commercialization beyond Q3 2026Action: Assess supply chain readiness, surgeon training programs, and marketing spend allocation to accelerate adoption.
- Cash Burn and Liquidity ManagementTrigger: Cash usage reduction of less than 50% compared to fiscal year 2025Action: Implement stricter operating expense controls and evaluate drawing down on the available $115 million credit facility.
Research as of 20 Jun 2026